ASX:PAB

Patrys (PAB) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
250,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
8.82%
Price Target
N/A
PAB stock logo

About Patrys Stock (ASX:PAB)

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. Patrys Limited was incorporated in 2006 and is based in Melbourne, Australia.

PAB Stock News Headlines

The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
The Best AI Stock to Own in the World Today is Trading for Just $25
“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.
See More Headlines
Receive PAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Patrys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/20/2019
Today
4/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-5,120,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.70 million

Miscellaneous

Outstanding Shares
2,060,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
0.36
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. James A. Campbell B.Sc.
    MBA, Ph.D., MD, CEO & Executive Director
  • Mr. Stefan Ross
    Company Secretary
  • Dr. Rebecca Tunstall
    Vice President of Corporate Development

PAB Stock Analysis - Frequently Asked Questions

How were Patrys' earnings last quarter?

Patrys Limited (ASX:PAB) released its quarterly earnings results on Wednesday, February, 20th. The company reported $0.00 EPS for the quarter.

What other stocks do shareholders of Patrys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Patrys investors own include Woolworths Group (WOW), Proteomics International Laboratories (PIQ), Insurance Australia Group (IAG) and Bendigo and Adelaide Bank (BEN).

This page (ASX:PAB) was last updated on 4/28/2024 by MarketBeat.com Staff

From Our Partners